A Rodríguez Núñez1, M Fonte2, E V S Faustino3. 1. Servicio de Críticos y Urgencias Pediátricas, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España. Electronic address: Antonio.Rodriguez.Nunez@sergas.es. 2. Unidade de Cuidados Intensivos Pediátricos e Servizo de Transporte Pediátrico, Hospital São João, Porto, Portugal. 3. Yale School of Medicine, New Haven, Connecticut, Estados Unidos.
Abstract
INTRODUCTION: Although critically ill children may be at risk from developing deep venous thrombosis (DVT), data on its incidence and effectiveness of thromboprophylaxis are lacking. OBJECTIVE: To describe the use of thromboprophylaxis in critically ill children in Spain and Portugal, and to compare the results with international data. MATERIAL AND METHODS: Secondary analysis of the multinational study PROTRACT, carried out in 59 PICUs from 7 developed countries (4 from Portugal and 6 in Spain). Data were collected from patients less than 18 years old, who did not receive therapeutic thromboprophylaxis. RESULTS: A total of 308 patients in Spanish and Portuguese (Iberian) PICUS were compared with 2176 admitted to international PICUs. Risk factors such as femoral vein (P=.01), jugular vein central catheter (P<.001), cancer (P=.03), and sepsis (P<.001), were more frequent in Iberian PICUs. The percentage of patients with pharmacological thromboprophylaxis was similar in both groups (15.3% vs. 12.0%). Low molecular weight heparin was used more frequently in Iberian patients (P<.001). In treated children, prior history of thrombosis (P=.02), femoral vein catheter (P<.001), cancer (P=.02) and cranial trauma or craniectomy (P=.006), were more frequent in Iberian PICUs. Mechanical thromboprophylaxis was used in only 6.8% of candidates in Iberian PICUs, compared with 23.8% in the international PICUs (P<.001). CONCLUSIONS: Despite the presence of risk factors for DVT in many patients, thromboprophylaxis is rarely prescribed, with low molecular weight heparin being the most used drug. Passive thromboprophylaxis use is anecdotal. There should be a consensus on guidelines of thromboprophylaxis in critically ill children.
INTRODUCTION: Although critically ill children may be at risk from developing deep venous thrombosis (DVT), data on its incidence and effectiveness of thromboprophylaxis are lacking. OBJECTIVE: To describe the use of thromboprophylaxis in critically ill children in Spain and Portugal, and to compare the results with international data. MATERIAL AND METHODS: Secondary analysis of the multinational study PROTRACT, carried out in 59 PICUs from 7 developed countries (4 from Portugal and 6 in Spain). Data were collected from patients less than 18 years old, who did not receive therapeutic thromboprophylaxis. RESULTS: A total of 308 patients in Spanish and Portuguese (Iberian) PICUS were compared with 2176 admitted to international PICUs. Risk factors such as femoral vein (P=.01), jugular vein central catheter (P<.001), cancer (P=.03), and sepsis (P<.001), were more frequent in Iberian PICUs. The percentage of patients with pharmacological thromboprophylaxis was similar in both groups (15.3% vs. 12.0%). Low molecular weight heparin was used more frequently in Iberian patients (P<.001). In treated children, prior history of thrombosis (P=.02), femoral vein catheter (P<.001), cancer (P=.02) and cranial trauma or craniectomy (P=.006), were more frequent in Iberian PICUs. Mechanical thromboprophylaxis was used in only 6.8% of candidates in Iberian PICUs, compared with 23.8% in the international PICUs (P<.001). CONCLUSIONS: Despite the presence of risk factors for DVT in many patients, thromboprophylaxis is rarely prescribed, with low molecular weight heparin being the most used drug. Passive thromboprophylaxis use is anecdotal. There should be a consensus on guidelines of thromboprophylaxis in critically ill children.
Authors: Renee A Higgerson; Karla A Lawson; Leeann M Christie; Ann-Marie Brown; Jennifer A McArthur; Balagangadhar R Totapally; Sheila J Hanson Journal: Pediatr Crit Care Med Date: 2011-11 Impact factor: 3.624
Authors: Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Brian R Branchford; Peter Mourani; Lalit Bajaj; Marilyn Manco-Johnson; Michael Wang; Neil A Goldenberg Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: Edward Vincent S Faustino; Sonya Patel; Ravi R Thiagarajan; Deborah J Cook; Veronika Northrup; Adrienne G Randolph Journal: Crit Care Med Date: 2011-07 Impact factor: 7.598
Authors: Michael C McCrory; Kenneth M Brady; Clifford Takemoto; Joseph D Tobias; R Blaine Easley Journal: Pediatr Crit Care Med Date: 2011-01 Impact factor: 3.624
Authors: Edward Vincent S Faustino; Philip C Spinella; Simon Li; Matthew G Pinto; Petronella Stoltz; Joana Tala; Mary Elizabeth Card; Veronika Northrup; Kenneth E Baker; T Rob Goodman; Lei Chen; Cicero T Silva Journal: J Pediatr Date: 2012-08-09 Impact factor: 4.406